Clinical trial
GALLANT 9 Tesaglitazar vs. Placebo in Combination With Insulin
NCT00242372 · AstraZeneca, Industry · Terminated
Key facts
| NCT number | NCT00242372 |
|---|---|
| Title | GALLANT 9 Tesaglitazar vs. Placebo in Combination With Insulin |
| Official title | A 24-Week Randomised, Double-Blind, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Added to the Therapy of Patients With Type 2 Diabetes Poorly Controlled on Insulin |
| Lead sponsor | AstraZeneca, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | Tesaglitazar 0.5, Insulin at least 30 units/day |
| Enrollment | 370 |
| Start date | Aug 1, 2004 |
| Completion | Mar 1, 2006 |
| First posted | Oct 20, 2005 |
| Last update posted | Apr 22, 2009 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: